Volume 123, Issue 3, Pages 719-727 (September 2002) Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy  Robert J. Fontana, Hie-Won L. Hann, Robert P. Perrillo, John M. Vierling, Theresa Wright, Jorge Rakela, Gaya Anschuetz, Randy Davis, Stephen D. Gardner, Nathaniel A. Brown  Gastroenterology  Volume 123, Issue 3, Pages 719-727 (September 2002) DOI: 10.1053/gast.2002.35352 Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 1 Kaplan-Meier plot of patient survival in the entire cohort (n = 154), NS patients surviving <6 months (n = 25), and SURV patients, which includes patients surviving ≥6 months and those with less than 6 months of follow-up (n = 129). The actuarial 3-year survival in the SURV group was 88% and 73% in the overall group. Gastroenterology 2002 123, 719-727DOI: (10.1053/gast.2002.35352) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 2 Predicted 6-month survival in patients with HBV cirrhosis receiving lamivudine, using the model derived from our data set. Index = 0.5 × bili + 1.7 × creatinine + 1.8 × HBV DNA (0 or 1). Gastroenterology 2002 123, 719-727DOI: (10.1053/gast.2002.35352) Copyright © 2002 American Gastroenterological Association Terms and Conditions

Fig. 3 (A) Proportion of NS and SURV patients who became HBV DNA negative during the first 24 weeks of lamivudine treatment. (B) Median serum bilirubin levels in NS and SURV patients through week 24 of lamivudine treatment. (C) Median serum albumin levels in NS and SURV patients through week 24 of lamivudine treatment. Error bars for B and C represent 95% confidence intervals. Gastroenterology 2002 123, 719-727DOI: (10.1053/gast.2002.35352) Copyright © 2002 American Gastroenterological Association Terms and Conditions